A Study of SGN-CD228A in Advanced Solid Tumors

Conditions: Cutaneous Melanoma; Pleural Mesothelioma; Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma Intervention: Drug: SGN-CD228A Sponsor: Seattle Genetics, Inc. Not yet recruiting

https://clinicaltrials.gov/ct2/show/NCT04042480?lupd_s=07%2F04%2F2019&lupd_d...

Source: ClinicalTrials.gov - August 2, 2019 Category: Research Source Type: clinical trials

Related Links:

Translating Mesothelioma Molecular Genomics and Dependencies into Precision Oncology-Based Therapies

Publication date: Available online 20 September 2019Source: Seminars in Cancer BiologyAuthor(s): Trista K. Hinz, Lynn E. HeasleyAbstractMalignant pleural mesothelioma (MPM) is a rare, yet lethal asbestos-induced cancer and despite marked efforts to reduce occupational exposure, the incidence has not yet significantly declined. Since 2003, combined treatment with a platinum-based agent and pemetrexed has been the first-line therapy and no effective or approved second-line treatments have emerged. The seemingly slow advance in developing new MPM treatments does not appear to be related to a low level of clinical and pre-clin...

Source: Seminars in Cancer Biology - September 22, 2019 Category: Cancer & Oncology Source Type: research

A Study of SGN-CD228A in Advanced Solid Tumors

Source: ClinicalTrials.gov - August 2, 2019 Category: Research Source Type: clinical trials

The Master Registry of Oncology Outcomes Associated With Testing and Treatment

Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; S arcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; &n...

Source: ClinicalTrials.gov - July 22, 2019 Category: Research Source Type: clinical trials